ICU Medical (NASDAQ:ICUI) Issues FY 2026 Earnings Guidance

Key Points

• ICU Medical issued FY 2026 EPS guidance of $8.60–$9.00, above the analyst consensus estimate of $7.83.
• The company’s latest quarter exceeded expectations, with EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million compared with estimates of $533.44 million.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $172, while shares recently traded near $166.37.

ICU Medical (NASDAQ:ICUI - Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 8.600-9.000 for the period, compared to the consensus estimate of 7.830. The company issued revenue guidance of -.

Analyst Ratings Changes

Several equities analysts recently commented on ICUI shares. Sanford C. Bernstein lowered shares of ICU Medical to a "market perform" rating in a research report on Monday, June 15th. Piper Sandler dropped their price objective on ICU Medical from $178.00 to $163.00 and set an "overweight" rating for the company in a report on Friday, April 17th. BTIG Research began coverage on ICU Medical in a research report on Monday, June 15th. They issued a "buy" rating and a $170.00 target price on the stock. Weiss Ratings upgraded ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, July 23rd. Finally, KeyCorp boosted their price target on ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a research report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $172.00.

ICU Medical Trading Down 0.0%

Shares of ICUI stock traded down $0.03 during mid-day trading on Thursday, reaching $166.37. The company's stock had a trading volume of 359,613 shares, compared to its average volume of 291,923. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $4.16 billion, a PE ratio of 89.93, a price-to-earnings-growth ratio of 2.40 and a beta of 0.74. The company's 50 day simple moving average is $150.11 and its 200-day simple moving average is $140.65. ICU Medical has a 12-month low of $107.00 and a 12-month high of $176.27.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts predict that ICU Medical will post 6.51 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the company's stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 2.10% of the company's stock.

Institutional Trading of ICU Medical

Several large investors have recently modified their holdings of ICUI. Smartleaf Asset Management LLC boosted its holdings in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock valued at $128,000 after purchasing an additional 101 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at approximately $177,000. O Shaughnessy Asset Management LLC purchased a new position in shares of ICU Medical during the 4th quarter valued at approximately $203,000. Panagora Asset Management Inc. acquired a new stake in shares of ICU Medical during the fourth quarter worth approximately $205,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of ICU Medical during the fourth quarter worth approximately $216,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source